Neuro Endocrine (Carcinoid) Carcinoma - Pipeline Review, H1 2014
出 版 商：Global Markets Direct
出版日期：2014/02/28
頁 數：87頁
文件格式：PDF
價 格：
USD 2,000 (Single-User License)
USD 4,000 (Multi-User License)
USD 6,000 (Global-User License)
USD 4,000 (Multi-User License)
USD 6,000 (Global-User License)
Neuro Endocrine (Carcinoid) Carcinoma - Pipeline Review, H1 2014
Summary
Global Markets Direct’s, ‘Neuro Endocrine (Carcinoid) Carcinoma - Pipeline Review, H1 2014’, provides an overview of the Neuro Endocrine (Carcinoid) Carcinoma’s therapeutic pipeline.
This report provides comprehensive information on the therapeutic development for Neuro Endocrine (Carcinoid) Carcinoma, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Neuro Endocrine (Carcinoid) Carcinoma and special features on late-stage and discontinued projects.
Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.
The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.
Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.
Scope
- The report provides a snapshot of the global therapeutic landscape of Neuro Endocrine (Carcinoid) Carcinoma
- The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved in the therapeutics development for Neuro Endocrine (Carcinoid) Carcinoma and enlists all their major and minor projects
- The report summarizes all the dormant and discontinued pipeline projects
- A review of the Neuro Endocrine (Carcinoid) Carcinoma products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- A detailed assessment of monotherapy and combination therapy pipeline projects
- Coverage of the Neuro Endocrine (Carcinoid) Carcinoma pipeline on the basis of target, MoA, route of administration and molecule type
- Latest news and deals relating related to pipeline products
Reasons to buy
- Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Develop strategic initiatives by understanding the focus areas of leading companies
- Identify and understand important and diverse types of therapeutics under development for Neuro Endocrine (Carcinoid) Carcinoma
- Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
- Devise corrective measures for pipeline projects by understanding Neuro Endocrine (Carcinoid) Carcinoma pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
Summary
Global Markets Direct’s, ‘Neuro Endocrine (Carcinoid) Carcinoma - Pipeline Review, H1 2014’, provides an overview of the Neuro Endocrine (Carcinoid) Carcinoma’s therapeutic pipeline.
This report provides comprehensive information on the therapeutic development for Neuro Endocrine (Carcinoid) Carcinoma, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Neuro Endocrine (Carcinoid) Carcinoma and special features on late-stage and discontinued projects.
Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.
The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.
Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.
Scope
- The report provides a snapshot of the global therapeutic landscape of Neuro Endocrine (Carcinoid) Carcinoma
- The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved in the therapeutics development for Neuro Endocrine (Carcinoid) Carcinoma and enlists all their major and minor projects
- The report summarizes all the dormant and discontinued pipeline projects
- A review of the Neuro Endocrine (Carcinoid) Carcinoma products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- A detailed assessment of monotherapy and combination therapy pipeline projects
- Coverage of the Neuro Endocrine (Carcinoid) Carcinoma pipeline on the basis of target, MoA, route of administration and molecule type
- Latest news and deals relating related to pipeline products
Reasons to buy
- Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Develop strategic initiatives by understanding the focus areas of leading companies
- Identify and understand important and diverse types of therapeutics under development for Neuro Endocrine (Carcinoid) Carcinoma
- Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
- Devise corrective measures for pipeline projects by understanding Neuro Endocrine (Carcinoid) Carcinoma pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
Table of Contents
Table of Contents 2
List of Tables 5
List of Figures 6
Introduction 7
Global Markets Direct Report Coverage 7
Neuro Endocrine (Carcinoid) Carcinoma Overview 8
Pipeline Products for Neuro Endocrine (Carcinoid) Carcinoma - Overview 9
Pipeline Products for Neuro Endocrine (Carcinoid) Carcinoma - Comparative Analysis 10
Neuro Endocrine (Carcinoid) Carcinoma - Therapeutics under Development by Companies 11
Neuro Endocrine (Carcinoid) Carcinoma - Therapeutics under Investigation by Universities/Institutes 13
Neuro Endocrine (Carcinoid) Carcinoma - Pipeline Products Glance 14
Late Stage Products 14
Clinical Stage Products 15
Early Stage Products 16
Neuro Endocrine (Carcinoid) Carcinoma - Products under Development by Companies 17
Neuro Endocrine (Carcinoid) Carcinoma - Products under Investigation by Universities/Institutes 18
Neuro Endocrine (Carcinoid) Carcinoma - Companies Involved in Therapeutics Development 19
F. Hoffmann-La Roche Ltd. 19
Amgen Inc. 20
Ipsen S.A. 21
Novartis AG 22
Progenics Pharmaceuticals, Inc. 23
Lexicon Pharmaceuticals, Inc. 24
Jiangsu Hengrui Medicine Co., Ltd. 25
Camurus AB 26
Vascular Biogenics Ltd. 27
Advanced Accelerator Applications 28
Foresee Pharmaceuticals, LLC 29
Neuro Endocrine (Carcinoid) Carcinoma - Therapeutics Assessment 30
Assessment by Monotherapy Products 30
Assessment by Target 31
Assessment by Mechanism of Action 34
Assessment by Route of Administration 37
Assessment by Molecule Type 39
Drug Profiles 41
pasireotide - Drug Profile 41
Product Description 41
Mechanism of Action 41
R&D Progress 41
telotristat etiprate - Drug Profile 44
Product Description 44
Mechanism of Action 44
R&D Progress 44
bevacizumab - Drug Profile 46
Product Description 46
Mechanism of Action 46
R&D Progress 46
Lutathera - Drug Profile 50
Product Description 50
Mechanism of Action 50
R&D Progress 50
pasireotide LAR - Drug Profile 51
Product Description 51
Mechanism of Action 51
R&D Progress 51
ganitumab - Drug Profile 53
Product Description 53
Mechanism of Action 53
R&D Progress 53
VB-111 - Drug Profile 56
Product Description 56
Mechanism of Action 56
R&D Progress 56
octreotide acetate - Drug Profile 58
Product Description 58
Mechanism of Action 58
R&D Progress 58
Famitinib - Drug Profile 60
Product Description 60
Mechanism of Action 60
R&D Progress 60
MIP-1407 - Drug Profile 62
Product Description 62
Mechanism of Action 62
R&D Progress 62
FP-002 - Drug Profile 63
Product Description 63
Mechanism of Action 63
R&D Progress 63
Peptides For Cancer - Drug Profile 64
Product Description 64
Mechanism of Action 64
R&D Progress 64
BIM-23-A-758 - Drug Profile 65
Product Description 65
Mechanism of Action 65
R&D Progress 65
Neuro Endocrine (Carcinoid) Carcinoma - Recent Pipeline Updates 66
Neuro Endocrine (Carcinoid) Carcinoma - Dormant Projects 76
Neuro Endocrine (Carcinoid) Carcinoma - Discontinued Products 77
Neuro Endocrine (Carcinoid) Carcinoma - Product Development Milestones 78
Featured News & Press Releases 78
Oct 16, 2013: AAA reaches halfway recruitment milestone of cancer patients in Lutathera Pivotal Phase III trial 78
Sep 17, 2013: Ipsen announces positive top line results from phase III ELECT study of Somatuline in the control of symptoms in NET patients with a history of carcinoid syndrome 78
Jun 07, 2013: Cedars-Sinai Launches Phase III Clinical Trial Of Lutathera For Metastatic Carcinoid Cancer Patients 79
Oct 12, 2012: Lexicon Pharma Announces Positive Phase II Trial Results Of Telotristat Etiprate In Carcinoid Syndrome 80
Oct 12, 2012: Lexicon Pharma Initiates Phase III Clinical Trial Of Telotristat Etiprate In Patients With Carcinoid Syndrome 81
Mar 20, 2012: Lexicon's Telotristat Etiprate Receives FDA Orphan Drug Designation For Carcinoid Syndrome Treatment 82
Oct 22, 2011: Lexicon To Present Data From Phase II Clinical Studies Of Telotristat Etiprate At NANETS In Minneapolis, US 83
Aug 09, 2011: Lexicon Announces Positive Results From Phase II Trial Of Telotristat Etiprate In Carcinoid Syndrome 83
Dec 16, 2010: Advanced Accelerator Applications Receives GMP Approval To Manufacture Lutate For Treatment Of Neuroendocrine Tumors 84
Dec 02, 2010: Pfizer Receives European Approval For SUTENT For New Indication In Progressive Pancreatic Neuroendocrine Tumors 85
Appendix 86
Methodology 86
Coverage 86
Secondary Research 86
Primary Research 86
Expert Panel Validation 86
Contact Us 87
Disclaimer 87
List of Tables
Number of Products under Development for Neuro Endocrine (Carcinoid) Carcinoma, H1 2014 9
Number of Products under Development for Neuro Endocrine (Carcinoid) Carcinoma - Comparative Analysis, H1 2014 10
Number of Products under Development by Companies, H1 2014 12
Number of Products under Investigation by Universities/Institutes, H1 2014 13
Comparative Analysis by Late Stage Development, H1 2014 14
Comparative Analysis by Clinical Stage Development, H1 2014 15
Comparative Analysis by Early Stage Development, H1 2014 16
Products under Development by Companies, H1 2014 17
Products under Investigation by Universities/Institutes, H1 2014 18
Neuro Endocrine (Carcinoid) Carcinoma - Pipeline by F. Hoffmann-La Roche Ltd., H1 2014 19
Neuro Endocrine (Carcinoid) Carcinoma - Pipeline by Amgen Inc., H1 2014 20
Neuro Endocrine (Carcinoid) Carcinoma - Pipeline by Ipsen S.A., H1 2014 21
Neuro Endocrine (Carcinoid) Carcinoma - Pipeline by Novartis AG, H1 2014 22
Neuro Endocrine (Carcinoid) Carcinoma - Pipeline by Progenics Pharmaceuticals, Inc., H1 2014 23
Neuro Endocrine (Carcinoid) Carcinoma - Pipeline by Lexicon Pharmaceuticals, Inc., H1 2014 24
Neuro Endocrine (Carcinoid) Carcinoma - Pipeline by Jiangsu Hengrui Medicine Co., Ltd., H1 2014 25
Neuro Endocrine (Carcinoid) Carcinoma - Pipeline by Camurus AB, H1 2014 26
Neuro Endocrine (Carcinoid) Carcinoma - Pipeline by Vascular Biogenics Ltd., H1 2014 27
Neuro Endocrine (Carcinoid) Carcinoma - Pipeline by Advanced Accelerator Applications, H1 2014 28
Neuro Endocrine (Carcinoid) Carcinoma - Pipeline by Foresee Pharmaceuticals, LLC, H1 2014 29
Assessment by Monotherapy Products, H1 2014 30
Number of Products by Stage and Target, H1 2014 33
Number of Products by Stage and Mechanism of Action, H1 2014 36
Number of Products by Stage and Route of Administration, H1 2014 38
Number of Products by Stage and Molecule Type, H1 2014 40
Neuro Endocrine (Carcinoid) Carcinoma Therapeutics - Recent Pipeline Updates, H1 2014 66
Neuro Endocrine (Carcinoid) Carcinoma - Dormant Projects, H1 2014 76
Neuro Endocrine (Carcinoid) Carcinoma - Discontinued Products, H1 2014 77
List of Figures
Number of Products under Development for Neuro Endocrine (Carcinoid) Carcinoma, H1 2014 9
Number of Products under Development for Neuro Endocrine (Carcinoid) Carcinoma - Comparative Analysis, H1 2014 10
Number of Products under Development by Companies, H1 2014 11
Comparative Analysis by Early Stage Products, H1 2014 16
Assessment by Monotherapy Products, H1 2014 30
Number of Products by Top 10 Target, H1 2014 31
Number of Products by Stage and Top 10 Target, H1 2014 32
Number of Products by Top 10 Mechanism of Action, H1 2014 34
Number of Products by Stage and Top 10 Mechanism of Action, H1 2014 35
Number of Products by Top 10 Route of Administration, H1 2014 37
Number of Products by Stage and Top 10 Route of Administration, H1 2014 38
Number of Products by Top 10 Molecule Type, H1 2014 39
Number of Products by Stage and Top 10 Molecule Type, H1 2014 40
Table of Contents 2
List of Tables 5
List of Figures 6
Introduction 7
Global Markets Direct Report Coverage 7
Neuro Endocrine (Carcinoid) Carcinoma Overview 8
Pipeline Products for Neuro Endocrine (Carcinoid) Carcinoma - Overview 9
Pipeline Products for Neuro Endocrine (Carcinoid) Carcinoma - Comparative Analysis 10
Neuro Endocrine (Carcinoid) Carcinoma - Therapeutics under Development by Companies 11
Neuro Endocrine (Carcinoid) Carcinoma - Therapeutics under Investigation by Universities/Institutes 13
Neuro Endocrine (Carcinoid) Carcinoma - Pipeline Products Glance 14
Late Stage Products 14
Clinical Stage Products 15
Early Stage Products 16
Neuro Endocrine (Carcinoid) Carcinoma - Products under Development by Companies 17
Neuro Endocrine (Carcinoid) Carcinoma - Products under Investigation by Universities/Institutes 18
Neuro Endocrine (Carcinoid) Carcinoma - Companies Involved in Therapeutics Development 19
F. Hoffmann-La Roche Ltd. 19
Amgen Inc. 20
Ipsen S.A. 21
Novartis AG 22
Progenics Pharmaceuticals, Inc. 23
Lexicon Pharmaceuticals, Inc. 24
Jiangsu Hengrui Medicine Co., Ltd. 25
Camurus AB 26
Vascular Biogenics Ltd. 27
Advanced Accelerator Applications 28
Foresee Pharmaceuticals, LLC 29
Neuro Endocrine (Carcinoid) Carcinoma - Therapeutics Assessment 30
Assessment by Monotherapy Products 30
Assessment by Target 31
Assessment by Mechanism of Action 34
Assessment by Route of Administration 37
Assessment by Molecule Type 39
Drug Profiles 41
pasireotide - Drug Profile 41
Product Description 41
Mechanism of Action 41
R&D Progress 41
telotristat etiprate - Drug Profile 44
Product Description 44
Mechanism of Action 44
R&D Progress 44
bevacizumab - Drug Profile 46
Product Description 46
Mechanism of Action 46
R&D Progress 46
Lutathera - Drug Profile 50
Product Description 50
Mechanism of Action 50
R&D Progress 50
pasireotide LAR - Drug Profile 51
Product Description 51
Mechanism of Action 51
R&D Progress 51
ganitumab - Drug Profile 53
Product Description 53
Mechanism of Action 53
R&D Progress 53
VB-111 - Drug Profile 56
Product Description 56
Mechanism of Action 56
R&D Progress 56
octreotide acetate - Drug Profile 58
Product Description 58
Mechanism of Action 58
R&D Progress 58
Famitinib - Drug Profile 60
Product Description 60
Mechanism of Action 60
R&D Progress 60
MIP-1407 - Drug Profile 62
Product Description 62
Mechanism of Action 62
R&D Progress 62
FP-002 - Drug Profile 63
Product Description 63
Mechanism of Action 63
R&D Progress 63
Peptides For Cancer - Drug Profile 64
Product Description 64
Mechanism of Action 64
R&D Progress 64
BIM-23-A-758 - Drug Profile 65
Product Description 65
Mechanism of Action 65
R&D Progress 65
Neuro Endocrine (Carcinoid) Carcinoma - Recent Pipeline Updates 66
Neuro Endocrine (Carcinoid) Carcinoma - Dormant Projects 76
Neuro Endocrine (Carcinoid) Carcinoma - Discontinued Products 77
Neuro Endocrine (Carcinoid) Carcinoma - Product Development Milestones 78
Featured News & Press Releases 78
Oct 16, 2013: AAA reaches halfway recruitment milestone of cancer patients in Lutathera Pivotal Phase III trial 78
Sep 17, 2013: Ipsen announces positive top line results from phase III ELECT study of Somatuline in the control of symptoms in NET patients with a history of carcinoid syndrome 78
Jun 07, 2013: Cedars-Sinai Launches Phase III Clinical Trial Of Lutathera For Metastatic Carcinoid Cancer Patients 79
Oct 12, 2012: Lexicon Pharma Announces Positive Phase II Trial Results Of Telotristat Etiprate In Carcinoid Syndrome 80
Oct 12, 2012: Lexicon Pharma Initiates Phase III Clinical Trial Of Telotristat Etiprate In Patients With Carcinoid Syndrome 81
Mar 20, 2012: Lexicon's Telotristat Etiprate Receives FDA Orphan Drug Designation For Carcinoid Syndrome Treatment 82
Oct 22, 2011: Lexicon To Present Data From Phase II Clinical Studies Of Telotristat Etiprate At NANETS In Minneapolis, US 83
Aug 09, 2011: Lexicon Announces Positive Results From Phase II Trial Of Telotristat Etiprate In Carcinoid Syndrome 83
Dec 16, 2010: Advanced Accelerator Applications Receives GMP Approval To Manufacture Lutate For Treatment Of Neuroendocrine Tumors 84
Dec 02, 2010: Pfizer Receives European Approval For SUTENT For New Indication In Progressive Pancreatic Neuroendocrine Tumors 85
Appendix 86
Methodology 86
Coverage 86
Secondary Research 86
Primary Research 86
Expert Panel Validation 86
Contact Us 87
Disclaimer 87
List of Tables
Number of Products under Development for Neuro Endocrine (Carcinoid) Carcinoma, H1 2014 9
Number of Products under Development for Neuro Endocrine (Carcinoid) Carcinoma - Comparative Analysis, H1 2014 10
Number of Products under Development by Companies, H1 2014 12
Number of Products under Investigation by Universities/Institutes, H1 2014 13
Comparative Analysis by Late Stage Development, H1 2014 14
Comparative Analysis by Clinical Stage Development, H1 2014 15
Comparative Analysis by Early Stage Development, H1 2014 16
Products under Development by Companies, H1 2014 17
Products under Investigation by Universities/Institutes, H1 2014 18
Neuro Endocrine (Carcinoid) Carcinoma - Pipeline by F. Hoffmann-La Roche Ltd., H1 2014 19
Neuro Endocrine (Carcinoid) Carcinoma - Pipeline by Amgen Inc., H1 2014 20
Neuro Endocrine (Carcinoid) Carcinoma - Pipeline by Ipsen S.A., H1 2014 21
Neuro Endocrine (Carcinoid) Carcinoma - Pipeline by Novartis AG, H1 2014 22
Neuro Endocrine (Carcinoid) Carcinoma - Pipeline by Progenics Pharmaceuticals, Inc., H1 2014 23
Neuro Endocrine (Carcinoid) Carcinoma - Pipeline by Lexicon Pharmaceuticals, Inc., H1 2014 24
Neuro Endocrine (Carcinoid) Carcinoma - Pipeline by Jiangsu Hengrui Medicine Co., Ltd., H1 2014 25
Neuro Endocrine (Carcinoid) Carcinoma - Pipeline by Camurus AB, H1 2014 26
Neuro Endocrine (Carcinoid) Carcinoma - Pipeline by Vascular Biogenics Ltd., H1 2014 27
Neuro Endocrine (Carcinoid) Carcinoma - Pipeline by Advanced Accelerator Applications, H1 2014 28
Neuro Endocrine (Carcinoid) Carcinoma - Pipeline by Foresee Pharmaceuticals, LLC, H1 2014 29
Assessment by Monotherapy Products, H1 2014 30
Number of Products by Stage and Target, H1 2014 33
Number of Products by Stage and Mechanism of Action, H1 2014 36
Number of Products by Stage and Route of Administration, H1 2014 38
Number of Products by Stage and Molecule Type, H1 2014 40
Neuro Endocrine (Carcinoid) Carcinoma Therapeutics - Recent Pipeline Updates, H1 2014 66
Neuro Endocrine (Carcinoid) Carcinoma - Dormant Projects, H1 2014 76
Neuro Endocrine (Carcinoid) Carcinoma - Discontinued Products, H1 2014 77
List of Figures
Number of Products under Development for Neuro Endocrine (Carcinoid) Carcinoma, H1 2014 9
Number of Products under Development for Neuro Endocrine (Carcinoid) Carcinoma - Comparative Analysis, H1 2014 10
Number of Products under Development by Companies, H1 2014 11
Comparative Analysis by Early Stage Products, H1 2014 16
Assessment by Monotherapy Products, H1 2014 30
Number of Products by Top 10 Target, H1 2014 31
Number of Products by Stage and Top 10 Target, H1 2014 32
Number of Products by Top 10 Mechanism of Action, H1 2014 34
Number of Products by Stage and Top 10 Mechanism of Action, H1 2014 35
Number of Products by Top 10 Route of Administration, H1 2014 37
Number of Products by Stage and Top 10 Route of Administration, H1 2014 38
Number of Products by Top 10 Molecule Type, H1 2014 39
Number of Products by Stage and Top 10 Molecule Type, H1 2014 40
